Login / Signup

Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors.

Dimitrios Karagkounis
Published in: Drug and therapeutics bulletin (2023)
After initially being licensed as treatment for diabetes, the range of indications for sodium-glucose co-transporter 2 (SGLT2) inhibitors has expanded to include chronic heart failure and chronic kidney disease. This article provides an overview of some of the evidence that supports the use of SGLT2 inhibitors in the management of chronic heart failure and chronic kidney disease, discusses the safety of this group of drugs and considers the practical application of their use.
Keyphrases
  • chronic kidney disease
  • end stage renal disease
  • type diabetes
  • ejection fraction
  • cardiovascular disease
  • left ventricular
  • peritoneal dialysis
  • metabolic syndrome
  • combination therapy
  • weight loss